the aid library

LIST OPTIONS

Filter

708

Implementation of simultaneous diagnostic testing for COVID-19 and TB in high TB burden countries

Stop TB Partnership; WHO (2022) C_WHO

Tuberculosis (TB) is the deadliest infectious disease in most low- and middle-income countries, claiming more than 4,000 lives each day. The unprecedented COVID-19 pandemic has seriously impacted people with pre-existing health conditions. People with TB are usually more vulnerable to other infectio... more

Download (1421)

View PDF (2608)

Diagnóstico de Vibrio cholerae y Salmonella spp. por PCR

Organización Mundial de la Salud OMS (2010) C_WHO

Download (351)

View PDF (425)

Pénuries et disponibilité des antibiotiques utilisés en santé humaine et vétérinaire en France

World Health Organisation (WHO) (2023) C_WHO

Ce rapport présente une analyse de l'OMS sur les pénuries et le manque de disponibilité des antibiotiques hors brevet en France prenant en compte l'approche Une seule santé. Le rapport est organisé en deux sections : santé animale et santé humaine. Le rapport vise à donner un éclairage sur... more

Download (393)

View PDF (420)

Troubles anxieux chez l’enfant et l’adolescent - Nature, developpement, traitement et prevention

R. M. Rapee IACAPAP (2012) C2

Troubles anxieux Chapitre F.1 Edition en français Traduction : Jean-Philippe Raynaud Avec le soutien de la SFPEADA

External Link

A double dose of inequality; Pharma companies and the Covid-19 vaccines crisis

Amnesty International (2022) C2

22 Sept. 2021 The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi... more

Download (324)

View PDF (305)

Principles in using psychotropic medication in children and adolescents

B. Vitiello IACAPAP (2012) C2

Introduction Chapter A.7

Download (338)

View PDF (434)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (422)

View PDF (477)

Lineamientos para el Manejo Clínico y Operativo de la Tuberculosis Drogorresistente

J. A. Caminero, A. Van Deun, P. I. Fujiwara, et. al Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias (2013)

Download (356)

View PDF (356)

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Download (377)

View PDF (502)

Comparative Study of Pharmaceutical Waste Disposal in Ethiopia, Kenya, Sudan and Uganda

Iosue, S. PSA Tansforming The Supply Chain (2020) C1

Download (374)

View PDF (595)

Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID 19. Tercera versión, 1 de febrero del 2022
recommended

Organización Mundial de la Salud OMS OPS (2022) C_WHO

List of essential medicines for the management of patients admitted in intensive care units with a suspected or confirmed diagnosis of COVID 19. Third version, 1 February 2022

Download (670)

View PDF (771)

Democratic Republic of the Congo. Demographic and Health Survey 2013-14.Supplemental V accine -preventable Diseases Report

A. Rimoin; E. Okitolonda; R. Doshi; et al. USAID; WHO; PEPFAR; et al. (2015) C1

Download (1301)

View PDF (2496)

Guideline for Hand Hygiene in Health-Care Settings

Centers for Disease Control and Prevention CDC (2002)

Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force

Download (447)

View PDF (720)

Technique automatisée d’amplification de l’acide nucléique en temps réel pour la détection rapide et simultanée de la tuberculose et de la résistance à la rifampicine : Système Xpert MTB/RIF

Organisation mondiale de la Santé (2011) C_WHO

Download (320)

View PDF (463)

Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults

A. Locke, N. Kirst, C.G. Shultz American Academy of Family Physicians (2015) C2

Download (267)

View PDF (281)

Toolkit for research and development of paediatric antiretroviral drugs and formulations

World Health Organization (WHO); Unitaid; Unicef; et al. World Health Organization (WHO); Unitaid; Unicef; et al. (2018) C_WHO

WHO and UNITAID in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group

Download (353)

View PDF (524)

Практический справочник ВОЗ по туберкулезу. Модуль 4. Лечение. Лечение лекарственно-устойчивого туберкулеза

World Health Organization WHO (2021) C_WHO

The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ... more

Download (309)

View PDF (419)

Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement

World Health Organization WHO (2022) C_WHO

Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij... more

Download (301)

View PDF (253)

COVAX: Structure and Principles

World Health Organization WHO (2022) C_WHO

This document outlines the working structure and guiding principles for collaboration of COVAX, the Vaccines pillar of the Access to COVID-19 Tools Accelerator (ACT-A). The working structure of COVAX continues to adapt to emerging needs and the changing trajectory of the pandemic. Some components of... more

Download (189)

View PDF (282)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID 19. Tercera versión, 1 de febrero del 2022 recommended

Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID 19. Tercera versión, 1 de febrero del 2022
recommended